RELiZORB for Malabsorption Syndrome

This trial tests a new method to assist children with Short Bowel Syndrome (SBS). SBS hinders nutrient absorption, often requiring children to depend on intravenous (IV) nutrition, which can lead to serious complications. The trial explores a treatment called RELiZORB, a small device that aids in digesting fats in tube feedings, potentially reducing the need for IV nutrition. Children with SBS who require IV nutrition for more than half of their daily intake might be suitable candidates for this trial.

As an unphased trial, this study provides a unique opportunity for children to potentially benefit from an innovative treatment approach.

The trial does not specify if you need to stop taking your current medications. However, you cannot participate if you have used pancreatic enzymes, cisapride, or certain other medications within 30 days before screening.

Research has shown that RELiZORB is safe and generally well-tolerated. Studies have demonstrated that it helps patients absorb fats better by breaking them down before they enter the body, particularly benefiting those with conditions like cystic fibrosis.

RELiZORB is unique because it is designed to enhance the digestion of fats directly within the feeding tube system, which is particularly beneficial for individuals with malabsorption syndrome. Unlike standard care options that often rely on enzyme pills or dietary modifications, RELiZORB uses an innovative cartridge that breaks down fats into absorbable fatty acids and monoglycerides before they enter the body. This method not only simplifies the process for individuals who rely on tube feeding but also aims to reduce dependency on parenteral nutrition, which is a more invasive and complex treatment. Researchers are excited about RELiZORB because it offers a more efficient and potentially more comfortable way to manage malabsorption, improving nutritional uptake directly at the source.

Research has shown that RELiZORB, the treatment under study in this trial, helps people with digestion problems absorb fats more effectively. Studies found that RELiZORB use increases the amount of fatty acids in the blood, which are crucial for growth and energy. Patients using RELiZORB also reported fewer stomach issues, such as diarrhea, over time. Specifically, there was a noticeable improvement in growth, with steady increases in height and weight over a year. This suggests that RELiZORB is important for children with conditions that hinder fat absorption.¹²³⁶⁷